Collecting and tracking samples for cancer treatment evaluation
Official title: Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute
Run by National Institutes of Health Clinical Center (CC) · NCT03269578 · Data updated 2026-11-12
This study is trying to see how different cancer treatments affect patients over time by collecting and tracking samples from their blood and tumors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 120 Years |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | August 28, 2017 |
| Main results expected | May 23, 2027 |
| Study ends | May 30, 2027 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT03269578 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who are currently being evaluated or treated for cancer at the DTC.
✕Probably not a fit
Patients who are not being treated for cancer or benign tumors at the DTC will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to connect research sample and treatment data for patients evaluated or treated for cancer at the Developmental Therapeutics Clinic (DTC). Participants will provide consent for researchers to access their medical records and link data from multiple studies they have participated in. The study focuses on collecting various biological samples, including blood and tissue biopsies, to analyze tumor responses to different treatments over time. The goal is to understand the dynamics of cancer treatment and resistance by evaluating molecular changes associated with drug effects.
Why it matters
Potential benefit: If successful, this study could enhance understanding of cancer treatment responses and improve future therapeutic strategies.
How similar studies have gone: Other studies have successfully utilized similar approaches to connect research data across multiple trials, indicating potential for this methodology.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * Patients who are being evaluated and/or treated for cancer or benign tuumors in the Developmental Therapeutics Clinic at the NIH Clinical Center * Ability to understand and willingness to sign a written informed consent document indicating their willingness to have data from their tissue or biologic fluid research specimens and limited medial information used for research as outlined in this protocol and to allow protocol staff access to the CRIS database and their Medical Records Number (MRN). * Age greater than or equal to 18 years ECLUSION CRITERIA: None
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Alice P Chen, M.D. — National Cancer Institute (NCI)
- Study coordinator: Jennifer H Zlott
- Email: zlottjh@mail.nih.gov
- Phone: (240) 760-6046
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exploring the unmet needs of cancer survivors in Reggio Emilia
This study is trying to find out what cancer survivors need most after finishing their treatment to help improve their care and quality of life.
-
LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma
This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.